Theravance Biopharma (TBPH) Other Gross PP&E Adjustments (2016 - 2025)
Theravance Biopharma (TBPH) has disclosed Other Gross PP&E Adjustments for 13 consecutive years, with -$25.4 million as the latest value for Q3 2025.
- On a quarterly basis, Other Gross PP&E Adjustments rose 13.24% to -$25.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$25.4 million, a 13.24% increase, with the full-year FY2024 number at $1.5 million, changed N/A from a year prior.
- Other Gross PP&E Adjustments was -$25.4 million for Q3 2025 at Theravance Biopharma, up from -$26.5 million in the prior quarter.
- In the past five years, Other Gross PP&E Adjustments ranged from a high of $1.5 million in Q4 2024 to a low of -$42.5 million in Q1 2021.
- A 5-year average of -$31.4 million and a median of -$37.6 million in 2023 define the central range for Other Gross PP&E Adjustments.
- Peak YoY movement for Other Gross PP&E Adjustments: increased 0.37% in 2023, then rose 22.44% in 2025.
- Theravance Biopharma's Other Gross PP&E Adjustments stood at -$40.7 million in 2021, then surged by 100.7% to $287000.0 in 2022, then crashed by 13192.68% to -$37.6 million in 2023, then soared by 103.9% to $1.5 million in 2024, then tumbled by 1837.2% to -$25.4 million in 2025.
- Per Business Quant, the three most recent readings for TBPH's Other Gross PP&E Adjustments are -$25.4 million (Q3 2025), -$26.5 million (Q2 2025), and -$27.4 million (Q1 2025).